| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: j.gordon{at}bham.ac.uk
Following our previous description of the serotonin transporter (SERT) acting as a conduit to 5-hydroxytryptamine (5-HT)-mediated apoptosis, specifically in Burkitt's lymphoma, we now detail its expression among a broad spectrum of B cell malignancy, while exploring additional SERT substrates for potential therapeutic activity. SERT was readily detected in derived B cell lines with origins as diverse as B cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma. Concentration and timecourse kinetics for the antiproliferative and proapoptotic activities of the amphetamine derivatives fenfluramine (an appetite suppressant) and 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") revealed them as being similar to the endogenous indoleamine. A tricyclic antidepressant, clomipramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both being effective in the low micromolar range. A majority of neoplastic clones were sensitive to one or more of the serotonergic compounds. Dysregulated bcl-2 expression, either by t(14;18)(q32;q21) translocation or its introduction as a constitutively active transgene, provided protection from proapoptotic but not antiproliferative outcomes. These data indicate a potential for SERT as a novel anti-tumor target for amphetamine analogs, while evidence is presented that the seemingly more promising antidepressants are likely impacting malignant B cells independently of the transporter itself.
Key words: 5-hydroxytryptamine • Burkitt's lymphoma • B cell lymphoma
This article has been cited by other articles:
|
|
 |
|
  K. Aitchison, K. Datla, H. Rooprai, J. Fernando, and D. Dexter Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration J Psychopharmacol, August 1, 2010; 24(8): 1261 - 1268. [Abstract] [PDF]
|
|
|
|
 |
|
 E. C. Lauterbach, S. D. Shillcutt, J. Victoroff, K. L. Coburn, and M. F. Mendez Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications J Neuropsychiatry Clin Neurosci, May 1, 2010; 22(2): 130 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stebbing, T. Powles, S. Mandalia, M. Nelson, B. Gazzard, and M. Bower Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV J. Clin. Oncol., May 10, 2008; 26(14): 2305 - 2310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leon-Ponte,, G. P. Ahern, and P. J. O'Connell Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor Blood, April 15, 2007; 109(8): 3139 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Meredith, M. J. Holder, A. Rosen, A. D. Lee, M. J. S. Dyer, N. M. Barnes, and J. Gordon Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma PNAS, September 5, 2006; 103(36): 13485 - 13490. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
